The study tested how commercially-available cannabis products affect the experiences of exercising.
A study conducted by researchers at the University of Colorado, Boulder and the University of Colorado, Anschutz Medical Campus explored the effects of cannabis on exercise (1). The study, “Acute Effects of Ad Libitum Use of Commercially Available Cannabis Products on the Subjective Experience of Aerobic Exercise: A Crossover Study,” was published in December 2023 in the journal Sports Medicine and is reportedly the first of its kind in this subject area (1). In 2013, Colorado became the first state in the nation to begin legal recreational cannabis sales (2).
This study collected data and asked questions of 42 runners—who were also regular cannabis users—while exercising first without cannabis and after consuming a cannabis flower product, either a Δ9 tetrahydrocannabinol (THC) dominant or cannabidiol (CBD) dominant product (1). After their baseline measurements were taken, the volunteer participants ran for 30 minutes on a treadmill, then in a separate session repeated the activity after consuming cannabis (1). Both positive and negative effects were reported (1). The participants described a more positive exercise experience and runner’s high symptoms when exercising after consuming cannabis, particularly in the CBD group, but those in the THC group said running was noticeably more difficult (1,2). “The bottom-line finding is that cannabis before exercise seems to increase positive mood and enjoyment during exercise, whether you use THC or CBD. But THC products specifically may make exercise feel more effortful,” explained lead study author Laurel Gibson in CU Boulder Today (2).
In the abstract, the authors noted the common concern of the potential sedentary effects of cannabis combined with national increases in cannabis use in the nation (1). However, the authors also hypothesized that cannabis could help give a boost to people who struggle to exercise (2). “We have an epidemic of sedentary lifestyle in this country, and we need new tools to try to get people to move their bodies in ways that are enjoyable,” stated study author Angela Bryan (2). “If cannabis is one of those tools, we need to explore it, keeping in mind both the harms and the benefits.” One of the goals of the study in general was to provide health care providers and policymakers data to make more informed decisions, stated Gibson in an interview (2).
Hear one of our Noid Knowledge podcast guests, Steve Ellmore, describe his experience with cannabis and running in our Noid Factoid.
References
Ep 25: Cannabis Quality Differentiation Beyond Cannabinoid Content
February 28th 2025In this latest installment of Noid Knowledge we are joined by Julie Kowalski, a leading mind in analytical chemistry and cannabis testing. Julie has arranged a very compelling symposium for Pittcon entitled Cannabis Aroma: Advances and Challenges in Determining and Commercializing Cannabis Product Quality Attributes. It is taking place on Wednesday, March 5, 2025, starting at 9:30 AM in room 209. The session features top notch speakers, including several previous guests of this show, and yours truly, discussing the next generation of quality assessment in cannabis.
Ep 24, Part III: Data Transparency in Cannabis Testing with Yasha Kahn
December 26th 2024In the final part of this episode, Evan Friedmann and Yasha Kahn discuss the need for a national entity to centralize cannabis data collection, moving from snapshot data to continuous updates. They emphasize the importance of accurate lab data and adverse event tracking, suggesting QR codes on packaging to report issues. Yasha suggests harsher consequences for result manipulation and suggests collaboration between state departments and federal entities to support underfunded regulators. They also discuss the potential benefits of off-the-shelf testing and the importance of stability testing. Finally, Yasha shares his top three reading recommendations for the audience.